Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147731 · ClinicalTrials.gov registry record · Phase 1
A Drug Interaction Study With Albiglutide and Warfarin
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01147731 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 16 participants.
The verdict
NCT01147731, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This open-label study evaluates the pharmacokinetics of warfarin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of warfarin.
Interventions
- BIOLOGICAL warfarin plus albiglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-06-04 |
| Est. Completion | 2010-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147731
The ClinicalTrials.gov registry entry for NCT01147731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which warfarin plus albiglutide is the first listed.
NCT01147731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147731 about?
NCT01147731 is a clinical study titled "A Drug Interaction Study With Albiglutide and Warfarin". This open-label study evaluates the pharmacokinetics of warfarin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of warfarin.
What is the current status of trial NCT01147731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-06-04. Estimated completion is 2010-09-09.
What interventions are being tested in trial NCT01147731?
The interventions under investigation include: warfarin plus albiglutide (BIOLOGICAL).
Who is sponsoring clinical trial NCT01147731?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.